



### 3.4.6 Diagnosis and Treatment of Allergic Diseases



3 Research areas and groups

Publications: 67 | Q1: 27

#### COMPOSITION

**Santiago Eugenio Quirce Gancedo.**

Jefe de Servicio de Alergología. Hospital Universitario La Paz

- **María Teresa Caballero Molina.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Luisa Caballero Soto.** *Facultativo Especialista de Área en Farmacia hospitalaria. Hospital Universitario La Paz*
- **Francisco Javier Contreras Porta.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Leticia de las Vecillas Sánchez.** *Facultativo Especialista en Alergología. Hospital Universitario La Paz*
- **Francisco Javier Domínguez Ortega.** *Jefe de Sección de Alergología. Hospital Universitario La Paz*

- **Ana Fiandor Román.** *Jefe de Sección de Alergología. Hospital Universitario La Paz*
- **María del Mar Gandolfo Cano.** *Jefe de Sección de Alergología Infantil. Hospital Universitario La Paz*
- **Carmen Gómez Traseira.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Juan Alberto Luna Porta.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Magdalena Lluch Bernal.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Pedrosa Delgado.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Elsa Phillips Angles.** *Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz*
- **Mónica Rodríguez Álvarez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Rosa Rodríguez Pérez.** *Investigadora titular, jefe de laboratorio. Hospital Universitario La Paz*
- **Margarita Tomás Pérez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Inés Torrado Español.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*

#### STRATEGIC OBJECTIVES

- These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angioedema and drug allergies). The group's strategic research objectives include:
- The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile
- The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
- The study of the pathogenesis and treatment of eosinophilic diseases of the airways (asthma, eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis)
- The characterisation of various types of angioedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment
- Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs

#### RESEARCH LINES

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult to control asthma: study on the influence of common and occupational allergens, comorbidities and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved.
- Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.
- Identification and characterization of new environmental allergens and modulating factors of allergenicity.

**3** Research areas and groups

**RESEARCH ACTIVITY**

**Doctoral Theses**

- **Laorden Escudero D.** Evaluación de los criterios de super-responder y la escala FEOS como herramientas eficaces en valorar la respuesta al tratamiento biológico en el asma grave no controlada[dissertation]. Madrid: Universidad Autónoma de Madrid UAM: 2024(11/03/2024). Director: Álvarez-Sala Walther R, Quirce Gancedo SE
- **Laichez Sánchez F.** Relevancia y repercusión clínica de la sensibilización a Pru p 7 en nuestro medio[dissertation]. Madrid: Universidad Autónoma de Madrid UAM: 2024(01/07/2024). Director: Rodríguez Pérez R, Quirce Gancedo SE

**Publications**

- **Agache I, Annesi-Maesano I, Cecchi L, Biagioni B, Chung KF, Clot B, D'Amato G, Damialis A, del Giacco S, Domínguez-Ortega J, Galán C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Tummon F, Traidl-Hoffmann C, Walusiak-Skorupa J, Jutel M, Akdis CA.** EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures. *Allergy*. 2024; 79(7): 1656-86. Article. IF: 12.0; D1
- **Agache I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Biagioni B, Chung F, D'Amato G, Damialis A, Del Giacco S, De las Vecillas L, Domínguez-Ortega J, Galán C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Sousa-Pinto B, Salazar J, Rodríguez-Tanta LY, Cantero Y, Montesinos-Guevara C, Song Y, Alvarado-Gamarrá G, Sola I, Alonso-Coello P, Nieto-Gutiérrez W, Jutel M, Akdis CA.** The impact of indoor pollution on asthma-related outcomes: A systematic review for the EAACI guidelines on

environmental science for allergic diseases and asthma. *Allergy*. 2024; 79(7): 1761-88. Review. IF: 12.0; D1

- **Agache I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Rigau D, Rodríguez-Tanta LY, Nieto-Gutiérrez W, Song Y, Cantero-Fortiz Y, Roqué M, Vasquez JC, Sola I, Biagioni B, Chung F, D'Amato G, Damialis A, del Giacco S, Vecillas LD, Domínguez-Ortega J, Galán C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Sousa-Pinto B, Alonso-Coello P, Salazar J, Jutel M, Akdis C.** The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma. *Allergy*. 2024; 79(7): 1725-60. Review. IF: 12.0; D1
- **Agache I, Ricci-Cabello I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Biagioni B, Chung KF, D'Amato G, Damialis A, del Giacco S, de las Vecillas L, Domínguez-Ortega J, Galán C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Salazar J, Sousa-Pinto B, Colom M, Fiol-deRoque MA, López LG, Malih N, Moro L, Pardo MG, Pazo PG, Campos RZ, Saletti-Cuesta L, Akdis M, Alonso-Coello P, Jutel M, Akdis CA.** The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: Systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma. *Allergy*. 2024; 79(9): 2346-65. Article. IF: 12.0; D1
- **Almonacid C, Ausín P, Villacampa JM, Dávila I, Pinilla M, Domínguez-Ortega J.** Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease. *J Asthma Allergy*. 2024; 17: 1325-32. Article. IF: 3.0; Q2

- **Álvarez-Gutiérrez FJ, Casas-Maldonado F, Soto-Campos G, Blanco-Aparicio M, Delgado J, Galo AP, Quirce S, Plaza V.** Spanish Consensus on Remission in Asthma (REMAS). *Arch Bronconeumol*. 2024; 60(8): 503-9. Article. IF: 9.2; D1
- **Arismendi E, Puente-Maestu L, Domingo C, Dávila I, Quirce S, González-Barcala EJ, Crespo-Lessmann A, Sánchez-Jareño M, Rivas-Pardinas C, Cea-Calvo L.** Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life. *Chron Resp Dis*. 2024; 21: 14799731241273800. Article. IF: 2.3; Q2
- **Betancor D, Barroso B, Valverde-Monge M, Gómez-López A, Sastre J.** The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria. *Resp Med*. 2024; 226: 107609. Editorial Material. IF: 3.1; Q2
- **Betancor D, Otal M, Olaguibel JM, Rodrigo-Muñoz JM, Puebla MJA, Arismendi E, Barranco P, Barroso B, Bobolea , Cárdbaba B, Cruz MJ, Curto E, Del Pozo , Domínguez-Ortega J, González-Barcala EJ, Luna-Porta JA, Martínez-Rivera C, Mulla J, Muñoz X, Picado C, Plaza , Quirce S, Rial MJ, Roibás-Veiga , Soto-Retes L, Valero A, Valverde-Monge M, Sastre J.** Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort. *J Invest Allerg Clin*. 2024; 34(3): 192-5. Article. IF: 4.8; Q1
- **Betschel SD, Caballero T, Jones DH, Longhurst HJ, Manning M, van Kooten S, Heckmann M, Danese S, Goga L, Burnette AF.** The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. *Allergy Asthma Clin Immunol*. 2024; 20(1): 43. Article. IF: 2.4; Q2
- **Bourdin A, Brusselle G, Couillard S, Fajt ML,**

- Heaney LG, Israel E, Mcdowell J, Menzies-Gow A, Martin N, Mitchell PD, Petousi N, Quirce S, Schleich F, Pavord ID.** Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. *J Allergy Clin Immunol Pract*. 2024; 12(4): 809-23. Review. IF: 6.6; Q1
- **Bousquet J, Schünemann HJ, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, Bedbrook A, Czarlewski W, Hofmann-Apitius M, Litynska J, Vieira RJ, Anto JM, Fonseca JA, Brozek J, Bognanni A, Brussino L, Canonica GW, Cherez-Ojeda I, Cruz AA, de las Vecillas L, Dykewicz M, Gemicioglu B, Giovannini M, Haahtela T, Jacobs M, Jacomelli C, Klimek L, Kvedariene V, Larenas-Linnemann DE, Louis G, Lourenço O, Leemann L, Morais-Almeida M, Neves AL, Nadeau KC, Nowak A, Palamarchuk Y, Palkonen S, Papadopoulos NG, Parmelli E, Pereira AM, Pfaar O, Regateiro FS, Savouré M, Taborda-Barata L, Toppila-Salmi SK, Torres MJ, Valiulis A, Ventura MT, Williams S, Yepes-Nunez JJ, Yorgancioglu A, Zhang L, Zuberbier J, Latiff AHA, Abdullah B, Agache I, Al-Ahmad M, Al-Nesf MA, Al Shaikh NA, Amaral R, Anotegui IJ, Asllani J, Balotro-Torres MC, Bergman KC, Bernstein JA, Bindslev-Jensen C, Blaiss MS, Bonaglia C, Bonini M, Bossé I, Braido F, Caballero-Fonseca F, Camargos P, Carreiro-Martins P, Casale T, Castillo-Vizuete JA, Cecchi L, Teixeira MD, Chang YS, Loureiro CC, Christoff G, Ciprandi G, Cirule I, Correia-de-Sousa J, Costa EM, Cvetkovski B, de Vries G, Del Giacco S, Devillier P, Dokic D, Douagui H, Durham SR, Enecilla ML, Fiocchi A, Fokkens WJ, Fontaine JF, Gawlik R, Gereda JE, Gil-Mata S, Giuliano AFM, Gotua M, Gradauskiene B, Guzman MA, Hossny E, Hrubisko M, Iinuma T, Irani C, Ispayeva Z, Ivancevich JC, Jartti T, Jesenák MS, Julge K, Jutel M, Kaidashev I, Bennoor KS, Khaltaev N, Kirenga B, Kraxner H, Kull I, Kulus M, Kuna P, Kupczyk M, Kurchenko**



A, La Grutta S, Lane S, Miculinic N, Lee SM, Tuyet LLT, Lkhagvaa B, Louis R, Mahboub B, Makela M, Makris M, Maurer M, Melén E, Milenkovic B, Mohammad Y, Moniuszko M, Montefort S, Moreira A, Moreno P, Mullol J, Nadif R, Nakonechna A, Navarro-Locsin CG, Neffen HE, Nekam K, Niedozytko M, Nunes E, Nyembue D, O'Hehir R, Ollert M, Ohta K, Okamoto Y, Okubo K, Olze H, Padukudru MA, Palomares O, Pali-Scholl I, Panzner P, Palosuo K, Park HS, Passalacqua G, Patella V, Pawankar R, Pétré B, Pitsios C, Plavec D, Popov TA, Puggioni F, Quirce S, Raciborski F, Ramonaite A, Recto M, Repka-Ramirez S, Roberts G, Robles-Velasco K, Roche N, Rodriguez-Gonzalez M, Romualdez JA, Rottem M, Rouadi PW, Salapatas M, Sastre J, Serpa FS, Sayah Z,

Scichilone N, Senna G, Sisul JC, Solé D, Soto-Martínez ME, Sova M, Sozinova O, Stevanovic K, Ulrik CS, Szylling A, Tan FM, Tantilipikorn P, Todo-Bom A, Tomic-Spiric V, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Rostan MV, Sofiev M, Valovirta E, Van Eerd M, Van Ganse E, Vasankari T, Vichyanond P, Viegé G, Wallace D, Wang DY, Wasserman S, Wong G, Worm M, Yusuf OM, Zaitoun F, Zidarn M. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024). *J Allergy Clin Immunol Pract.* 2024; 12(10): 2648-68. Article. IF: 6.6; Q1

- Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Czarlewski W, Ansotegui IJ, Bergmann KC, Braidó F, Brussino L, Cecchi L, Loureiro CC, Cruz AA, Devillier P, Fiocchi A, Gemicioğlu B, Haahtela T, Ivancevich JC, Klimek L, Kulus M,

- Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Louis G, Louis R, Makris M, Morais-Almeida M, Niedozytko M, Ohta K, Ollert M, Papadopoulos N, Patella V, Pétré B, Pfaar O, Puggioni F, Quirce S, Regateiro FS, Roche N, Rouadi PW, Samolinski B, Sastre J, Schleich F, Scichilone N, Taborda-Barata L, Toppila-Salmi S, Valiulis A, Koyuncu IV, Ventura MT, Yorgancioglu A, Fonseca JA, Zuberbier T. Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air®. *Clin Transl Allergy.* 2024; 14(9): e12390. Article. IF: 4.0; Q2
- Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Fonseca JA, Zuberbier T. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases. *J Allergy Clin Immunol Pract.* 2024; 12(8): 2010-6. Article. IF: 6.6; Q1
- Buttgereit T, Aulenbacher F, Gutsche A, Kolkhir P, Weller K, Ayala CV, Magerl M, Farkas H, Grumach AS, Aygoeren-Puersuen E, Bara N, Ben-Shoshan M, Bernstein J, Betschel S, Bouillet L, Caballero T, Cancian M, Castaldo AJ, Cimbollek S, Cohn DM, Craig T, Fomina D, Gelincik A, Grivcheva-Panovska V, Jindal A, Katelaris C, Kessel A, Kinaciyan T, Longhurst HJ, Martínez-Saguer I, Riedl M, Schoeffl C, Staubach P, Zanichelli A, Zhi Y, Boysen HB, Fok JS, Li PH, Hakl R, Hide M, Peter J, Maurer M. The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation. *Clin Exp Allergy.* 2024; 54(9): 712-6. Article. IF: 5.2; Q1
- Caballero M, Quirce S. Highlighting the Need for Each Excipient to Appear Under a Single Name in All Products That Contain it to Guarantee Identification. *J Invest Allerg Clin.* 2024; 34(4): 280-1. Letter. IF: 4.8; Q1
- Caballero ML, Quirce S. Allergological reappraisal of the Annex to the European Commission guideline on excipients (SANTE-2017-11,668). *Allergy.* 2024; 79(3): 735-9. Letter. IF: 12.0; D1
- Caballero T, Alonso C, Baeza ML, Baynova

- K, Cabeza J, Cortés I, Oblitas DE, Guilarte M, Joral A, Palomo JJ, Jiménez MAL, Virto AM, Medrano L, Boquet EM, Navarro M, Pérez D, Martí MJ, Foltz SLS, Suero C, Zamora C. Hereditary angioedema in Spain: medical care and patient journey. *Orphanet J Rare Dis.* 2024; 19(1): 210. Article. IF: 3.5; Q2
- Camino-Mera A, Pardo-Seco J, Bello X, Argiz L, Boyle RJ, Custovic A, Herberg J, Kaforou M, Arasi S, Fiocchi A, Pecora V, Barni S, Mori F, Bracamonte T, Echeverría L, O'Valle-Aisa V, Hernández-Martínez NL, Carballeira I, García E, García-Magan C, Moure-Gonzalez JD, Gonzalez-Delgado P, Garriga-Baraut T, Infante S, Zambrano-Ibarra G, Tomas-Pérez M, Machinena A, Pascal M, Prieto A, Vazquez-Cortes S, Fernández-Rivas M, Vila L, Alsina L, Torres MJ, Mangone G, Quirce S, Martinon-Torres F, Vazquez-Ortiz M, Gomez-Carballa A, Salas A. Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome. *Clin Exp Allergy.* 2024; 54(11): 919-29. Article. IF: 5.2; Q1
- Cerecedo I, López-Picado A, Hernández-Núñez MG, Rubio-Herrera MA, de la Hoz B, Infante S, Vázquez-Cortés S, Ruano EJ, Gómez-Traseira C, Freundt-Serpa NP, Martínez-Botas J, Fernández-Rivas M. Milk Ladder for Reintroduction of Cow's Milk in Infants With IgE-Mediated Cow's Milk Allergy: Version Adapted to the Spanish Population. *J Invest Allerg Clin.* 2024; 34(1): 51-3. Editorial Material. IF: 4.8; Q1
- Colque-Bayona M, Hernández-Cano N, Tomás-Pérez M, Caballero T, Quirce S, Domínguez-Ortega J. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. *J Asthma.* 2024; 61(7): 762-5. Article. IF: 1.3; Q3
- De Agrela-Mendes I, Pedrosa M, Gómez-Traseira C, Phillips-Anglés E, Rodríguez-Alvarez M, Quirce S. Tolerance of peanuts and tree nuts in Spanish children with exclusive sensitization to lipid transfer proteins. *Pediat*

- Allerg Imm-Uk. 2024; 35(7): e14204. Article. IF: 4.5; Q2
- **de las Vecillas L, Quirce S.** The Multiple Trajectories of the Allergic March. *J Invest Allerg Clin.* 2024; 34(2): 75-84. Review. IF: 4.8; Q1
  - **de Llano LP, Urrutia I, Cosío BG, Gullón-Blanco JA, Mena AH, Cisneros C, Martínez-Moragón E, Malanda NM, Esquerre MM, Quirce S, Rivas DD.** Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients. *Allergy.* 2024; 79(8): 2235-40. Article. IF: 12.0; D1
  - **Domingo C, Quirce S, Dávila I, Crespo-Lessman A, Arismendi E, De Diego A, González-Barcala EJ, de Llano LP, Cea-Calvo L, Sánchez-Jareño M, López-Cotarelo P, Puente-Maestu L.** Cough severity visual analog scale scores and quality of life in patients with refractory or unexplained chronic cough. *Respir Investig.* 2024; 62(6): 987-94. Article. IF: 2.0; Q3
  - **Domínguez-Ortega J, Colás C, Romero JD, Mena AH, Ferrer AM, Sanz PB, Montaña PP, Lázaro JF, Bonilla PG, Melcón MG, Bernal MML, Pérez RG, Antolin-Amérigo D, Lacomba JM, Santiago ALV, Sánchez-García S, Del Cuvillo A.** Baseline Clinical Characteristics and Phenotypes of Patients With Severe Asthma in Alergodata: The Spanish Allergy Society Registry. *J Invest Allerg Clin.* 2024; 34(2): 135-8. Editorial Material. IF: 4.8; Q1
  - **Domínguez-Ortega J, Laorden D, Vilchez-Sánchez F, Bañas-Conejero D, Quirce S.** Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. *J Asthma.* 2024; 61(1): 39-47. Article. IF: 1.3; Q3
  - **Domínguez-Ortega J, Muñoz-Gall X, Delgado-Romero J, Casas-Maldonado F, Blanco-Aparicio M.** Challenges in the Implementation of the Spanish Consensus on the Reduction of Oral Corticosteroids: Insights From the Medical Community. *Open Respir Arch.* 2024; 6(3): 100331. Article. Not Indexed
  - **Doyen V, Miguères N, Frère A, Walusiak-Skorupa J, Wiszniewska M, Suojalehto H, Munoz X, Romero-Mesones C, van Kampen V, Sastre J, Quirce S, Barranco P, Riffart C, de Blay F, Vandenplas O.** Diagnostic Accuracy of Specific IgE Against Wheat and Rye in Flour-Induced Occupational Asthma. *J Allergy Clin Immunol Pract.* 2024; 12(8): 2017-25. Article. IF: 6.6; Q1
  - **Entrala A, Loli-Ausejo D, Pérez T, Losantos , Cabañas R, Caballero T.** Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH. *J Invest Allerg Clin.* 2024; 34(4): 261-3. Editorial Material. IF: 4.8; Q1
  - **Esteban-Gorgojo I, Gorgojo MP, Sastre J, García-Río F, Quirce S.** The Influence of BMI in Asthma: Which Traits Are due to Obesity and Which to the Asthma and Obesity Phenotype? *J Invest Allerg Clin.* 2024; 34(1): 30-7. Article. IF: 4.8; Q1
  - **Fernández-Concha I, Pose K, de las Vecillas L, Lluch-Bernal M, Tomás-Pérez M, Soto T, de la Guía AL, Cabañas R.** Successful Desensitization to Lenalidomide in Leukocytoclastic Vasculitis. *J Invest Allerg Clin.* 2024; 34(5): 352-3. Editorial Material. IF: 4.8; Q1
  - **Gil-Mata S, Teixeira T, Bedbrook A, Bousquet J, Sousa-Pinto B, Vieira RJ.** Perceptions of the impact of individual allergic rhinitis symptoms: A survey of ARIA clinical experts. *World Allergy Organ J.* 2024; 17(12): 100999. Article. IF: 4.3; Q2
  - **Giovannini M, Beken B, Agache I, Akdis CA, Carvalho D, Chivato T, Comberati P, de las Vecillas L, Eguiluz-Gracia I, Heffler E, Jutel M, Karabacak DE, Kolkhir P, Moya B, Ollert M, O'Neil S, Santos AF, Schwarze J, Skevaki C, Sokolowska M, Tsilochristou O, van Wijk RG, del Giacco S, Riggioni C.** Mentoring as the cornerstone of continued education in Allergy and Clinical Immunology: 10th anniversary of the EAACI mentorship program. *Allergy.* 2024; 79(1): 7-11. Editorial Material. IF: 12.0; D1
  - **Granda P, Villamañán E, Carpio C, Laorden D, Quirce S, Alvarez-Sala R.** Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects? *J Asthma.* 2024; 61(8): 857-66. Article. IF: 1.3; Q3
  - **Granda P, Villamañán E, Heinz S, Laorden D, Romero D, Añón JM, Carpio C, Sobrino C, Collada , Domínguez-Ortega J, Herrero A, Quirce S, Álvarez-Sala R.** Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. *J Invest Allerg Clin.* 2024; 34(1): 60-1. Editorial Material. IF: 4.8; Q1
  - **Granda P, Villamañán E, Laorden D, Carpio C, Collada V, Domínguez-Ortega J, de las Vecillas L, Romero-Ribate D, Chaparro-Díaz OF, Miguel-Sin TL, Alloca-Alvarez DJ, Correa-Borít JM, Losantos I, Mir-Ihara P, Narváez-Fernández EJ, Quirce S, Álvarez-Sala R.** Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2. *J Clin Med.* 2024; 13(15): 4299. Article. IF: 2.9; Q1
  - **Jiménez-Rodríguez TW, de las Vecillas L, Labella M, Lynch DM, Besz KM, Marquis K, Burgos A, Gomis VS, Lozano I, Antón RAM, de la Calle FM, Delgado MPG, Gutiérrez A, Montenegro E, Rodríguez F, Sánchez E, Castells M.** Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization. *Allergy.* 2024; 79(3): 679-89. Article. IF: 12.0; D1
  - **Kiani-Alikhan S, Gower R, Craig T, Wedner J, Kinacian T, Aygören-Pürsün E, Banerji A, Bernstein JA, Anderson J, Collis P, Johnston DT, Desai B, Tomita D, Gagnon R, Tachdjian R, Soteres DF, Farkas H, Caballero T, Mcneil D, Jacobs J, Lumry WR.** Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APEX-2 Randomized Trial. *J Allergy Clin Immunol Pract.* 2024; 12(3): 733-43. Article. IF: 6.6; Q1
  - **Klimek L, Chaker A, Hox V, Del Giacco S, Gevaert P, Shamji M, Salmi ST, Bonadonna P, Walusiak-Skorupa J, Morreira A, Palomares O, Pfaar O, Gracia IE, Arasi S, Solano JM, Reitsma S, Mösges R, Gane S, Hagemann J, van Gerven L, Schiappoli M, Lundberg M, Doan S, Karavelia A, Santamaria RF, de las Vecillas L, Giovannini M, Riggioni C, Comberati P, Correia M, Hannachi F, Carvalho D, Trikamjee T, Perea AA, Castagnoli R, Khaleva E, Barni S, Tsilochristou O, Quecchia C, Vijverberg S, Kolkhir P, Bussolino C, Arcolaci A, Sava F, Boccabella C, Moya B, Karabacak DE, Beken B, Graessel A, Akdis CA, Torres MJ.** Professor Peter Valentin Tomazic, Graz, Austria. *Allergy.* 2024; 79(8): 2311-2. Article. IF: 12.0; D1
  - **Laorden D, Hernández I, Domínguez-Ortega J, Romero D, Álvarez-Sala R, Quirce S.** A real-life cohort of mepolizumab treatment in severe eosinophilic asthma. *Eur Ann Allergy Clin Immunol.* 2024; 56(4): 169-75. Article. IF: 2.3; Q3
  - **Lluch-Bernal M, Pedrosa M, Domínguez-Ortega J, Colque-Bayona M, Correa-Borít J, Phillips-Anglés E, Gómez-Traseira C, Quirce S, Rodríguez-Pérez R.** Sensitization to Quercus ilex Pollen Is Clinically Relevant in Patients With Seasonal Pollen Allergy. *J Invest Allerg Clin.* 2024; 34(5): 338-40. Article. IF: 4.8; Q1
  - **Lluncor-Salazar M, Phillips-Anglés E, Pedrosa M, Lamacchia D, Hernandez A, Prior N, Cabanas R, Caballero T.** Determinants of Disease Activity in Adults With Hereditary Angioedema due to C1-Esterase Inhibitor Deficiency. *J Invest Allerg Clin.* 2024; 34(6): 406-9. Editorial Material. IF: 4.8; Q1
  - **Miguères N, Vandenplas O, Walusiak-Skorupa J, Wiszniewska M, Munoz X, Romero-Mesones C, Suojalehto H, Lindström , van Kampen , Merget R, Mason P, Maestrelli P, Sastre J, Quirce S, Riffart C, Godet J, de Blay F.** Sputum Inflammatory Patterns Are Associated With Distinct Clinical Characteristics in Patients with Occupational Asthma Independently of the Causal Agent. *J Invest Allerg Clin.* 2024; 34(2): 85-96. Article. IF: 4.8; Q1
  - **Miralles-López JC, Álvarez-Gutiérrez F, Delgado-Romero J, Quirce S, Soto-Campos JG, Andújar-Espinosa R, Cabrejos-Perotti S, Castilla-Martínez M, Flores-Martín I, Pajarón-Fernández MJ, Valverde-Molina J.** Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus). *J Asthma Allergy.* 2024; 17: 1163-71. Article. IF: 3.0; Q2
  - **Miralles-López JC, Antolin-Amérigo D, García-Moguel , Domínguez-Ortega J, Delgado-Romero J, Quirce S.** Positioning of Tezepelumab in Severe Asthma. *J Invest Allerg Clin.* 2024; 34(1): 1-11. Review. IF: 4.8; Q1

- **Mir-Ihara P, Vecillas LD, Heredia R, Fiandor A, González-Muñoz M, Zamarrón E, Prados C, Cabañas R.** Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test. *J Invest Allerg Clin.* 2024; 34(3): 211-3. Article. IF: 4.8; Q1
- **Mullol J, Sastre J, Domínguez-Ortega J, Blanco-Aparicio M, Vizuete JAC, Alobid I, García-Vitoria M, Palomo-Jiménez PI.** Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain. *Rhinology.* 2024; 62(4): 421-31. Article. IF: 6.8; D1
- **Narváez-Fernández E, Pose K, Caballero ML, Rodríguez-Pérez R, Quirce S.** Occupational Asthma and Food Allergy due to Soybean in a Bakery Worker. *J Invest Allerg Clin.* 2024; 34(3): 207-9. Article. IF: 4.8; Q1
- **Pascal M, Bax HJ, Bergmann C, Bianchini R, Castells M, Chauhan J, de las Vecillas L, Hartmann K, Alvarez El, Jappe U, Jimenez-Rodriguez TW, Knol E, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Karagiannis SN.** Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper. *Allergy.* 2024; 79(9): 2319-45. Article. IF: 12.0; D1
- **Plaza V, Trigueros JA, Carretero JA, Arranz IO, Chicote JMV, Sánchez CA, Tomás JB, Serrano CC, Juncal LD, Domínguez-Ortega J, Rivero JF, Campos JGS, Fernández EM, Martínez S, Lacomba JM, Quirce S.** Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force. *J Invest Allerg Clin.* 2024; 34(4): 257-60. Editorial Material. IF: 4.8; Q1
- **Plaza V, Blanco M, Ferreira J, García G, Morete A, Quirce S, Soto-Campos G, Almonacid C.** Highlights of the Spanish Asthma Guidelines (GEMA), Version 5.4. *Open Respir Arch.* 2024; 6(4): 100356. Editorial Material. Not Indexed
- **Podder I, Salman A, Asero R, Caballero MT, Caffarelli C, De las Vecillas L, Gimenez-Arnau AM, Giovannini M, Kocatürk E, Kolkhir P, Manti S, Cascales TN, Maurer M.** Biological drugs for the treatment of children with chronic spontaneous urticaria. *Expert Rev Clin Immunol.* 2024; 20(12): 1427-35. Review. IF: 3.7; Q2
- **Poole JA, Zamora-Sifuentes JL, de las Vecillas L, Quirce S.** Respiratory Diseases Associated With Organic Dust Exposure. *J Allergy Clin Immunol Pract.* 2024; 12(8): 1960-71. Article. IF: 6.6; Q1
- **Pose K, Narváez-Fernández E, de la Guía AL, De Las Vecillas L, Domínguez-Ortega J, Lluch-Bernal M, Fiando A, Cabañas R.** A Tailored 7-to 10-Day Lenalidomide Desensitization Protocol. *J Invest Allerg Clin.* 2024; 34(1): 49-50. Editorial Material. IF: 4.8; Q1
- **Presa IJ, Sala-Cunill A, Martí-Garrido J, Cid MN, Vargas SIC, Mendizábal SL, Sánchez MTA, González PR, Quirce S, Hernández MCS, Badas AJ, Vidal C, Antolin-Américo D, Veleiro B, Sastre ML.** Profile of Patients With Moderate-to-Severe Atopic Dermatitis and Chronic Urticaria Undergoing Biological Treatment in Hospital Allergy Units in Spain: First Report of the Alergodata Registry. *J Invest Allerg Clin.* 2024; 34(2): 131-3. Editorial Material. IF: 4.8; Q1
- **Reshef A, Buttgerit T, Betschel SD, Caballero T, Farkas H, Grumach AS, Hide M, Jindal AK, Longhurst H, Peter J, Riedl MA, Zhi YX, Aberer W, Abuzakouk M, Al Farsi T, Al Sukaiti N, Al-Ahmad M, Alrichter S, Aygören-Pürsüm E, Baeza ML, Bara NA, Bauer A, Bernstein JA, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Bygum A, Calderon O, Campos RD, Romero FHC, Cancian M, Chong-Neto HJ, Christoff G, Cimbollek S, Cohn DM, Craig T, Danilycheva I, Darlenski R, Du-Thanh A, Ensina LF, Fomina D, Fonacier L, Fukunaga A, Gelincik A, Giavina-Bianchi P, Godse K, Gompels M, Goncalo M, Gotua M, Guidos-Fogelbach G, Guilarte M, Kasperska-Zajac A, Katelaris CH, Kinaciyan T, Kolkhir P, Kulthanan K, Kurowski M, Latysheva E, Lauerma A, Launay D, Leonart R, Lumry W, Malbran A, Ali RM, Nasr I, Nieto-Martínez S, Parisi C, Pawankar R, Piñero-Saavedra M, Popov TA, Porebski G, García AP, Pyatilova P, Rudenko M, Sekerel BE, Serpa FS, Sheikh F, Siebenhaar F, Soria A, Staevska M, Staubach P, Stobiecki M, Thomsen SF, Triggiani M, Valerieva A, Valle S, Van Dinh N, Ayala CEV, Zalewska-Janowska A, Zanichelli A, Magerl M, Maurer M.** Definition, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. *J Allergy Clin Immunol.* 2024; 154(2): 398-411. Article. IF: 11.2; D1
- **Rodríguez-Pérez R, Del Pozuelo S, Pulido E, Brigido C, Carretero P, Caballero ML.** Chemiluminescence-Based IgE Dot-Blot Assay in the Diagnosis of Anaphylaxis Caused by Prontosan. *J Invest Allerg Clin.* 2024; 34(2): 141-2. Editorial Material. IF: 4.8; Q1
- **Scadding GK, Gray C, Conti DM, McDonald M, Backer V, Scadding G, Bernal-Sprekelsen M, De Corso E, Diamant Z, Hopkins C, Jesenak M, Johansen P, Kappen J, Mullol J, Price D, Quirce S, Reitsma S, Toppila-Salmi S, Senior B, Thyssen JP, Wahn U, Hellings PW.** Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma. *Front Allergy.* 2024; 5: 1404735. Review. IF: 3.1; Q2
- **Scadding GK, McDonald M, Backer V, Scadding G, Bernal-Sprekelsen M, Conti DM, De Corso E, Diamant Z, Gray C, Hopkins C, Jesenak M, Johansen P, Kappen J, Mullol J, Price D, Quirce S, Reitsma S, Salmi S, Senior B, Thyssen JP, Wahn U, Hellings PW.** Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1-allergic asthma. *Front Allergy.* 2024; 4: 1291185. Review. IF: 3.1; Q2
- **Sousa-Pinto B, Vieira RJ, Marques-Cruz M, Bognanni A, Gil-Mata S, Jankin S, Amaro J, Pinheiro L, Mota M, Giovannini M, de las Vecillas L, Pereira AM, Litynska J, Samolinski B, Bernstein J, Dykewicz M, Hofmann-Apitius M, Jacobs M, Papadopoulos N, Williams S, Zuberbier T, Fonseca JA, Cruz-Correira R, Bousquet J, Schünemann HJ.** Artificial Intelligence-Supported Development of Health Guideline Questions. *Ann Intern Med.* 2024; 177(11): 1518-29. Article. IF: 15.2; D1
- **Suhaimi AH, Rajendram A, Khaidizar FD, Mir P, Pulido-Lucas E, Quirce S, Pedrosa M, Rodríguez-Pérez R, Al-Idrus A.** Occurrences of allergenicity to banana pathogenesis-related-10 (PR10) protein variants. *Food Funct.* 2024; 15(23): 11715-25. Article. IF: 5.4; Q1
- **Tómas-Pérez M, Alonso AT, Montoro-Ferrer A, Domínguez-Ortega J, Galindo-Bonilla PA, Castelló MC, Naves JE, Ausín P.** Concomitant Efficacy of Dupilumab in Treating Eosinophilic Esophagitis and Type 2 Asthma. *J Invest Allerg Clin.* 2024; 34(6): 412-4. Editorial Material. IF: 4.8; Q1
- **Valerieva A, Caballero T, Magerl M, Frade JP, Audhya PK, Craig T.** Advent of oral medications for the treatment of hereditary angioedema. *Clin Transl Allergy.* 2024; 14(9): e12391. Review. IF: 4.0; Q2
- **Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, Arismendi E, Bobolea I, Cárdbaba B, Cruz MJ, Del Pozo V, Domínguez-Ortega J, González-Barcala EJ, Olaguibel JM, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Peleteiro-Pedraza L, Valles CP, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Sastre J.** Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients. *Arch Bronconeumol.* 2024; 60(1): 23-32. Article. IF: 9.2; D1
- **Vieira RJ, Azevedo LF, Pereira AM, Nogueira-Leite D, Gonçalves FNR, Larenas-Linnemann DE, Cruz AA, Gemicioglu B, Samolinski B, de las Vecillas L, Giovannini M, Cunha MJ, Rodrigues J, Kvedariene V, Klimek L, Pfaar O, Zuberbier T, Fonseca JA, Bousquet J, Sousa-Pinto B.** Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study. *J Allergy Clin Immunol Pract.* 2024; 12(11): 3107-15. Article. IF: 6.6; Q1
- **Villamañán E, Laorden D, Granda P, Sobrino C, De Andrés S, Carpio C, Domínguez-Ortega J, Romero D, Mariscal P, de las Vecillas L, Quirce**

**S, alvarez-Sala R, AsmaGrave HULP Study Grp.** Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met? *J Clin Med.* 2024; 13(23): 7152. Review. IF: 2.9; Q1

#### Research projects

- **Caballero Molina MT.** Desarrollar las tareas necesarias para poner en marcha el proyecto angiocare 2021. Ediciones Mayo S.A. 2022-Ongoing. **Managment centre:** FIBHULP
- **Caballero Molina MT.** Development and transcultural validation of an international specific questionnaire (IHAE-QoL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DITV-IHAE-QoL). *Hereditary Angio-Edema In.* 2009-Ongoing. **Managment centre:** FIBHULP
- **Caballero Molina MT.** Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). *ISCI.* 2020-2024. **Managment centre:** FIBHULP
- **Caballero Molina MT.** Impacto humanístico y económico del angioedema hereditario en España. Estudio Impactaeh. *Shire International GmbH.* 2021-Ongoing. **Managment centre:** FIBHULP
- **de las Vecillas Sánchez L.** Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones inmediatas y tardías. *Fundación de la Sociedad Española de Alergología e Inmunología Clínica.* 2022-Ongoing. **Managment centre:** FIBHULP
- **Domínguez Ortega FJ.** Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen gramíneas. *Inmunotek.* 2015-Ongoing. **Managment centre:** FIBHULP
- **Domínguez Ortega FJ.** Estudio de coste-

efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. *Glaxosmithkline S. A.* 2021-Ongoing. **Managment centre:** FIBHULP

- **Quirce Gancedo SE.** Integra: utilidad de los ratios en el diagnóstico alergológico: de la investigación a la práctica clínica. *Thermo Fisher Diagnostics S.L.U.* 2022-Ongoing. **Managment centre:** FIBHULP
- **Quirce Gancedo SE.** Relación entre asma y obesidad en la población española mayor o igual a 18 años. *Novartis Farmaceutica S.A.* 2009-Ongoing. **Managment centre:** FIBHULP
- **Quirce Gancedo SE.** Sesiones en investigación del diagnóstico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alérgica y alergia a alimentos. *Thermo Fisher Diagnostics S.L.U.* 2017-Ongoing. **Managment centre:** FIBHULP
- **Rodríguez Pérez MR.** Caracterización alérgica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221 ). *ISCI.* 2023-2025. **Managment centre:** FIBHULP
- **Rodríguez Pérez MR.** Evaluación de la capacidad alérgica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. *Angulas Aguinaga S. A. U.* 2018-Ongoing. **Managment centre:** FIBHULP
- **Tomás Pérez M.** Efectividad de la inmunoterapia sublingual de ltp (slit melocoton) en pacientes con alergia a melocoton y otros vegetales por sensibilización a ltp en condiciones de práctica clínica habitual. *Alk-Abello S.A.* 2020-Ongoing. **Managment centre:** FIBHULP

#### Cibers and Retics

- **Caballero Molina MT.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). *ISCI.* (31/12/2024). FIBHULP

#### Clinical trials

- **Caballero Molina MT.** estudio de fase iiib, global, multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib 25 mg b.i.d., en comparación con placebo, con omalizumab 300 mg cada 4 semanas como control activo, a lo largo de 52 semanas en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos h1 de segunda generación.  
**Type/Phase:** III  
**Sponsored by:** Novartis Pharma Services Ag  
**Signature date:** 15/02/2024
- **Domínguez Ortega FJ.** tyrex: estudio observacional retrospectivo para evaluar el impacto del tratamiento con mepolizumab a los 5 años en pacientes con asma grave en vida real en España.  
**Type/Phase:** EPA-OD  
**Sponsored by:** Glaxosmithkline S.A.  
**Signature date:** 26/06/2024
- **Phillips Anglés E.** estudio en fase iii para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario.  
**Type/Phase:** III  
**Sponsored by:** Biocryst Pharmaceuticals Inc.  
**Signature date:** 08/07/2024
- **Tomás Pérez M.** estudio observacional, multicéntrico, prospectivo, para evaluar la efectividad y seguridad en vida real de depigoid® perro (100 dpp/ml) en pacientes con rinitis/rinoconjuntivitis persistente moderada-grave con o sin asma alérgica controlada en España.  
**Type/Phase:** EOm prospectivo  
**Sponsored by:** Leti Pharma S.L.U.  
**Signature date:** 25/01/2024

#### Patents and trademarks

- **Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee.** Novel wheat allergens. PCT/SE2008/051377,

EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

- **Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee.** Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. *CM* 13.083.068; 2014 July 15.

**HAE-QoL**  
 HEREDITARY ANGIOEDEMA QUALITY OF LIFE

- **Sánchez Herrerros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees.** Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.
- **del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.** In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.
- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** *Expertasma.* N°018981670; 2024 June 14.

